Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice-Reference-Cited by-同舟云学术

Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

Published:2022-05-07 Issue:17 Volume:28 Page:1814-1829
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Silva-Veiga Flavia Maria,Miranda Carolline Santos,Vasques-Monteiro Isabela Macedo Lopes,Souza-Tavares Henrique,Martins Fabiane Ferreira,Daleprane Julio Beltrame,Souza-Mello Vanessa

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference45 articles.

1. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. The Epidemiology of Obesity: A Big Picture

3. Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose

4. PPAR-α activation counters brown adipose tissue whitening: a comparative study between high-fat– and high-fructose–fed mice

5. Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications;Inflammopharmacology;2024-08-19

2. Anti-steatotic effects of PPAR-alpha and gamma involve gut-liver axis modulation in high-fat diet-fed mice;Molecular and Cellular Endocrinology;2024-05

3. Time-dependent impact of a high-fat diet on the intestinal barrier of male mice;World Journal of Methodology;2024-03-20

4. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome;iScience;2024-02

5. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases;mBio;2024-01-16